The acquisition includes nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, Influenza A and B virus and RS virus for units of HUSLAB and ISLAB. This is a joint acquisition described by the parties in this invitation to tender. The abbreviation “Subscriber” is used for the parties involved in this call for tenders.

Tests for procurement for GeneXpert (Cepheid), Novodiag (Hologic), Cobas Liat (Roche) equipment in laboratories, as well as Genomera (Abacus diagnostica) hardware in ISLAB laboratories. Tests should be CE IVD labeled for nasopharyngeal samples. The test price shall include the necessary cartridges and reagents with delivery costs. More specifically, the acquisition includes the acquisition of the following tests for the above equipment: indication of InfA/B/RSV nucleic acid, SARS-CoV2 nucleic acid indication, InfA/B/RSV/SARS CoV2 nucleic acid indication.

The acquisition is divided into four subdivisions:

1. Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, influenza A and B virus and RS virus for GeneXpert (Cepheid) hardware (HUSLAB and ISLAB)

2. Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, influenza A and B virus and RS virus for Novodiag (Hologic) hardware (HUSLAB and ISLAB)

3. Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, influenza A and B virus and RS virus for Cobas Liat (Roche) (HUSLAB and ISLAB)

4. Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, influenza A and B virus and RS virus for the Genomera (Abacus diagnostica) apparatus (ISLAB)

Subdivisions 1 and 3 also include the possibility of acquiring option equipment.

All aspects are individually compared, meaning the supplier does not have to provide a test for all the areas mentioned. The bidder may make up to one bid for each subdivision. Subdivision intra-division offers are allowed. It is not allowed to make parallel bids.

The acquisition is contracted for a two (2) year contract period. The contract may be extended (on a sub-divisional basis) for two one-year option periods (1+1).

The contract period begins once both sides have signed an agreement. The object of the acquisition and its requirements are described in detail in the call for tender and its annexes.

Subdivision 1: Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, Influenza A and B virus and RS virus for the GeneXpert (Cepheid), according to the Request for Tender and its Attachments to HUSLAB and ISLAB.

The Subscriber will select one (1) supplier with whom it will contract.

Subdivision 2: Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, Influenza A and B virus and RS virus for the Novodiag (Hologic) equipment in accordance with the request for tender and its attachments to the units of HUSLAB and ISLAB.

The Subscriber will select one (1) supplier with whom it will contract.

Subdivision 3: Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, Influenza A and B virus and RS virus for Cobas Liat (Roche) in accordance with the request for tender and its attachments to the units of HUSLAB and ISLAB.

The Subscriber will select one (1) supplier with whom it will contract.

Subdivision 4: Nucleic acid demonstration tests for rapid diagnostics of SARS-CoV-2, Influenza A and B virus and RS virus for the Genomera (Abacus diagnostica) equipment in accordance with the request for tender and its attachments to ISLAB units.

The Subscriber will select one (1) supplier with whom it will contract.